Quest Diagnostics Incorporated
Every calculator, already run for DGX
Open the full toolkit →You have the numbers on DGX. Get the argument.
A written report on which of these readings actually decide the outcome for Quest Diagnostics Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering DGXAnalyst Price Target Disagreement for Quest Diagnostics Incorporated
Wall Street's bull case implies +8% from the current price; the bear case implies -17%. Analysts are relatively aligned on DGX's range.
Ownership & short interest
Insider Trading Activity for DGX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service c…
DGX — frequently asked
Is DGX a buy right now?
Wall Street's consensus rating on Quest Diagnostics Incorporated is Buy across 17 analysts, with a mean price target of $247.40 (+0% vs. the current $246.45). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is DGX overvalued?
DGX trades at 26.2x trailing earnings, against a DCF fair value of $282 per share. The current price implies 4% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is DGX's next earnings date?
Quest Diagnostics Incorporated is next scheduled to report earnings around Oct 20, 2026. A full DGX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Quest Diagnostics Incorporated?
Analysts covering Quest Diagnostics Incorporated (DGX) range from a bear-case target of $204.00 to a bull-case high of $265.00, with a mean consensus target of $247.40 across 15 analysts. The spread of $61.00 (25% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Quest Diagnostics Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Quest Diagnostics Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full DGX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Quest Diagnostics Incorporated, in minutes. 3 free reports included with every account — no credit card required.